This IDC Market Perspective provides IDC Health Insights' review of key Q3 2019 IT deals, news, and digital initiatives in the European life sciences industry. In the evolving industry environment in Europe, it is critical for life sciences companies to closely follow the fast-moving trends and developments to promptly spot favorable opportunities and remain competitive in the market. This is the fifth in the quarterly series of reports IDC Health Insights has released following the expansion of its in-depth research coverage of life sciences markets across Europe.
"Digital patient engagement and patient omni-experience transformation is at the forefront of digital innovation efforts in the European life sciences industry. As life sciences companies in Europe are moving forward to find new paths to innovation, patient engagement initiatives are evolving around multiple touchpoints across the entire patient journey," said Nino Giguashvili, senior research analyst, IDC Health Insights Europe. "In Q3, supply chain modernization efforts were underway among organizations supplying pharmaceutical to the EU markets, and many are still facing problems with meeting the primary requirements of the EU's Falsified Medicines Directive. Meanwhile, the pharmaceutical market in Russia is starting to present growing opportunities for pharma serialization and track-and-trace solution vendors, in an anticipation of stringent drug traceability regulations planned for enforcement in early 2020."